Business Context and Reporting Period
Company: Veracyte, Inc. (VCYT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Veracyte is a global diagnostics company providing genomic tests for cancer diagnosis, prognosis, and treatment decisions. Key products include Decipher Prostate (prostate cancer), Afirma (thyroid cancer), Prosigna (breast cancer), and Decipher Bladder (bladder cancer). The company operates via Laboratory Developed Tests (LDTs) in the U.S. and In Vitro Diagnostics (IVDs) internationally. In 2024, the company acquired C2i Genomics to expand into Minimal Residual Disease (MRD) testing.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $517.1 million | $445.8 million | +16% |
| Testing Revenue | $493.2 million | $419.0 million | +18% |
| Product Revenue | $14.3 million | $13.7 million | +5% |
| Gross Profit | $362.5 million | $298.1 million | +22% |
| Gross Margin | 70.1% | 66.9% | +320 bps |
| Net Income | $66.4 million | $24.1 million | +175% |
| Diluted EPS | $0.82 | $0.31 | +165% |
| Operating Cash Flow | $136.3 million | $75.1 million | +81% |
| Cash & Short-term Investments | $412.9 million | $289.4 million | +43% |
| Total Test Volume | 179,528 | 152,750 | +18% |
Note: The company reported a $20.5 million non-cash impairment charge in 2025 related to the divestiture of its French subsidiary, Veracyte SAS.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by an 18% increase in testing revenue, fueled by a 27% volume increase in Decipher Prostate tests and an 11% increase in Afirma tests.
- Profitability Surge: Net income increased 175% year-over-year, aided by revenue growth, improved gross margins, and a $15.3 million benefit from the revaluation of acquisition-related contingent consideration.
- Strategic Divestiture: In August 2025, the company divested the contract manufacturing portion of Veracyte SAS (France) to Helio Diagnostics SAS. This resulted in a $20.5 million impairment charge and a $6.7 million loss on deconsolidation, though it streamlined operations.
- Cost Management: Cost of testing revenue grew 11%, slower than revenue growth, indicating operational leverage. Selling and marketing expenses increased 5% due to headcount additions and merit increases.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- New Product Launches: The company expects to launch Prosigna as an LDT in the U.S. and its first MRD test (TrueMRD for muscle-invasive bladder cancer) in the first half of 2026. Management does not expect these to contribute meaningfully to revenue in 2026.
- Reimbursement: Decipher Prostate now has Medicare coverage for metastatic indications (effective Oct 2024). Afirma GSC coverage was expanded in July 2024. The company anticipates PAMA data reporting in mid-2026 could impact reimbursement rates effective 2027.
- Capital Allocation: The company maintains a strong balance sheet with $412.9 million in cash and short-term investments, sufficient to fund operations and growth without immediate need for external financing.
Risks and Contingencies
- Regulatory Uncertainty: Potential changes in FDA regulation of Laboratory Developed Tests (LDTs) and evolving EU IVDR requirements pose risks to the business model.
- Geopolitical Risk: Operations in Israel (C2i Genomics) face risks from the ongoing conflict in the Middle East, though a ceasefire was in place as of the filing date.
- Supplier Concentration: Reliance on sole-source suppliers for critical reagents and equipment (e.g., NanoString/Bruker for Prosigna) creates supply chain vulnerability.
- Reimbursement Dependency: Revenue is heavily dependent on Medicare (33%) and UnitedHealthcare (14%). Changes in payer policies or PAMA rates could materially impact margins.
Investor Verification Checklist
- Reimbursement Rates: Verify the impact of the upcoming PAMA data reporting cycle (May-July 2026) on future Medicare reimbursement rates for Decipher and Afirma.
- 2026 Launch Execution: Monitor the successful commercial launch and reimbursement approval for the Prosigna LDT and TrueMRD MRD test in 2026.
- France Divestiture Impact: Confirm that the transition of manufacturing to Helio Diagnostics SAS is proceeding without disruption to Prosigna IVD supply.
- Israel Operations: Assess any ongoing operational disruptions or employee mobilization impacts at the C2i facility in Haifa due to regional conflict.
- Valuation Allowance: Track the potential release of the valuation allowance on deferred tax assets, which could result in a future tax benefit if profitability is sustained.